ioMicroglia APOE4 Het hero image FINAL

cat no | io1033, io1034

ioMicroglia APOE 4/3 C112R/WT

Human iPSC-derived Alzheimer's disease model

ioMicroglia APOE 4/3 are opti-ox™ precision reprogrammed microglia carrying a genetically engineered heterozygous C112R mutation in the APOE gene, converting the wild-type APOE3 allele to APOE4, encoding the apolipoprotein E4. The APOE4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease (AD). 

These cells offer a functional, rapidly maturing, and disease relevant system to study the role of APOE4 in late-onset AD, alongside a genetically matched wild-type control.

 


Request a quote >

 

Place your order

Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.

per vial

Add to basket

Click here for bulk request

Benchtop benefits

comparison_0

Making True Comparisons

Pair the ioDisease Model Cells with the genetically matched wild-type ioMicroglia to directly investigate the effect of APOE4 on late-onset AD.

quick_0

Quick

Rapidly maturing cells that are ready to use within 10 days post-revival, in mono- and co-cultures.

functional_0

Functional

Disease model cells display key phagocytic and cytokine secretion functions.

Technical data

Cells arrive ready to plate

bit.bio_ioMicroglia_timeline_horizontal_withoutdox

ioMicroglia APOE 4/3 are delivered in a cryopreserved format and are programmed to rapidly mature upon revival in the recommended media. The protocol for the generation of these cells is a three-phase process: an Induction phase that is carried out at bit.bio, Phase 1: Stabilisation for 24 hours, Phase 2: Maturation for a further 9 days, Phase 3: the Maintenance phase. Cells are ready to use from day 10.

Highly characterised and defined

Disease model cells express key microglia markers comparably to the genetically matched wild-type control
ioMicroglia APOE4 Het P2RY12 panel_FINAL2 compressed
ioMicroglia APOE4 Het IBA1 panel_FINAL2
Immunofluorescent staining on day 10 post-revival demonstrates similar homogenous expression of microglia markers P2RY12 and IBA1 and ramified morphology in both disease model clones compared to the genetically matched wild-type (WT) control. 100X magnification.
Disease model cells show expected ramified morphology by day 10
ioMicroglia APOE4 Het Morphology panel compressed

Both disease model clones mature rapidly and key ramified morphology can be identified by day 4 and continues through to day 10, similarly to the WT control. Day 1 to 10 post-thawing; 100x magnification.

 

Key cytokine secretion function

Disease model cells display reduced secretion of  pro-inflammatory cytokines, IL-12p70, IL-1β, and TNF⍺, upon activation compared to the genetically matched wild-type control

ioMicroglia APOE4 Het cytokine graphs FINAL

Cytokine secretion was analysed at day 10 post-revival after stimulation with LPS 100 ng/ml and IFNɣ 20 ng/ml for 24 hours. This revealed that both disease model clones secrete the pro-inflammatory cytokines, IL-12p70, IL-1β, and TNF⍺ at a lower-level than the WT control whereas IL-6 and IL-8, appear to be secreted at a similar level to the WT control. Clone CL53 secretes the anti-inflammatory IL-10 at a lower level whereas clone CL80 secretes this cytokine at a similar level to the WT control. Supernatants were harvested and analysed using MSD V-plex Proinflammatory Kit™. Three technical replicates were performed per experiment. 

Product information

Starting material

Human iPSC line

Seeding compatibility

6, 12, 24, 96 & 384 well plates

Shipping info

Dry ice

Donor

Caucasian adult male (skin fibroblast)

Vial size

Small: >1.5 x 10⁶ viable cells

Quality control

Sterility, protein expression (ICC), functional phagocytosis and cytokine secretion assays

Differentiation method

opti-ox cellular reprogramming

Recommended seeding density

37,000 to 39,500 cells/cm²

User storage

LN2 or -150°C

Format

Cryopreserved cells

Product use

ioCells are for research use only

Genetic modification

Heterozygous C112R mutation in the APOE gene

Applications

Alzheimer's disease modelling
Drug discovery and development
Neuroinflammation modelling
Phagocytosis assays
cytokine response assays
Co-culture studies

Available clones

io1033S: ioMicroglia APOE 4/3 C112R/WT (CL53)
io1034S: ioMicroglia APOE 4/3 C112R/WT (CL80)

Product resources

Generation and characterisation of a panel of human iPSC-derived neurons and microglia carrying early and late onset relevant mutations for Alzheimer’s disease Poster
Generation and characterisation of a panel of human iPSC-derived neurons and microglia carrying early and late onset relevant mutations for Alzheimer’s disease
Smith et al. 
bit.bio
2024
Downlaod
ioMicroglia™ and related disease models User manual
ioMicroglia™ and related disease models

V6

bit.bio

2023

Download
Mastering Cell Identity In A Dish: The Power Of Cellular Reprogramming Webinar
Mastering Cell Identity In A Dish: The Power Of Cellular Reprogramming

Prof Roger Pedersen | Adjunct Professor and Senior Research Scientist at Stanford University 

Dr Thomas Moreau | Director of Cell Biology Research | bit.bio

Watch now
Rethinking Developmental Biology With Cellular Reprogramming Webinar
Rethinking Developmental Biology With Cellular Reprogramming

Mark Kotter | CEO and founder | bit.bio

Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology |  Stanford University

Watch now

Alzheimer’s Disease Pathogenesis - Emerging Role of Microglia

In this GEN webinar, hear from our distinguished expert, Dr Matthias Pawlowski, and learn about the emerging role of microglia in the pathogenesis of Alzheimer’s disease and their potential as a therapeutic target to treat this disease effectively.

5C_ioMicrogliaConfocal image-1-1

Related products

ioMicroglia APOE 4/4 C112R/C112R™ ioDisease Model Cells
ioMicroglia APOE 4/4 C112R/C112R™ cat no. io1031 | io1032
Order now
ioMicroglia TREM2 R47H/WT™ ioDisease Model Cells
ioMicroglia TREM2 R47H/WT™ cat no. io1038
Order now
ioMicroglia TREM2 R47H/R47H™ ioDisease Model Cells
ioMicroglia TREM2 R47H/R47H™ cat no. io1035 | io1036
Order now
ioMicroglia™ ioWild Type Cells
ioMicroglia™ cat no. io1021
Order now
ioGABAergic Neurons APP V717I/WT™ ioDisease Model Cells
ioGABAergic Neurons APP V717I/WT™ cat no. io1084 | io1085
Order now
ioGABAergic Neurons APP V717I/V717I™ ioDisease Model Cells
ioGABAergic Neurons APP V717I/V717I™ cat no. io1081 | io1082
Order now
ioGABAergic Neurons™ ioWild Type Cells
ioGABAergic Neurons™ cat no. io1003
Order now
ioGlutamatergic Neurons™ ioWild Type Cells
ioGlutamatergic Neurons™ cat no. io1001
Order now

Related pages

Discover ioCells Learn about our range of human iPSC-derived cells for research and drug discovery
Resources Explore our latest scientific insights, webinars, blogs and videos
Our platform Discover the cell identity coding platform that powers our ioCells